Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cellomics Inc.

www.cellomics.com

Latest From Cellomics Inc.

Beckman Coulter's Play for High Growth

With the Coulter integration successful, Beckman Coulter looks for high-growth opportunities outside of its traditional businesses. Beckman, through internal efforts in its life sciences business and a series of small alliances, is making a play in genomics and proteomics. In addition to building up near-term revenues, the aim is to find new "content" in the form of assays for its clinical business.
BioPharmaceutical Medical Device

Cytokinetics: A Platform Case Study for the Next Decade

Cytokinetics' plan to become a drug discovery company and ASP depends on an innovative technology platform, consisting of a program that targets the cell's cytoskeletal structure to develop novel therapeutics, and one in cellular bioinformatics, designed to unlock the lead optimization bottleneck by automating cell biology. The company has impressive talent and investors, along with some promising early validation of its technology. But it has yet to sign up any pharmaceutical company partners or customers. And it is selling to a skeptical industry that over the last decade has bought into a number of new technologies offering partial solutions to inefficiencies in the drug discovery process, without improving productivity in terms of generating pharmacologically acceptable lead compounds. Thus, the question facing Cytokinetics is how much will Big Pharma pay for potential discovery breakthrough technologies, and will it be enough for the biotech to validate their science. It's also a question likely to confront other emerging platform companies as they increasingly find themselves the sole entrants in their fields, and in the position of having to create their own markets.
BioPharmaceutical Strategy

Start-Ups in High Throughput Screening

Companies in the new generation of screening technologies are stressing content as much as they're stressing speed, and one-stop shopping as much as focused expertise.
BioPharmaceutical Strategy

Cellomics Inc.

Cellomics Inc. aims to use its screening technology to determine the activity of a drug at the cellular level.
BioPharmaceutical Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Biological Detection Systems
  • BioDx
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Cellomics Inc.
  • Senior Management
  • L. Robert Johnston Jr., EVP, CFO
    Paul Kinnon, VP, Sales
    William T Sharp, VP, Bus. Dev.
  • Contact Info
  • Cellomics Inc.
    Phone: (412) 770-2200
    100 Technology Drive
    Pittsburgh, PA 15238
    USA
UsernamePublicRestriction

Register